Industry Insights

  1. 5 Cost Savers From Selling Your Surplus Biopharmaceutical Equipment

    Selling or disposing of surplus and unused manufacturing and packaging equipment can provide cash to your business from otherwise idled “assets.” 

  2. 5 Biggest Trends Of Oligonucleotide Manufacturing In 2022 2/18/2022

    The rapidly growing market for Oligonucleotide manufacturing represents an opportunity for investors and pharma companies that wish to produce novel pharmaceutical products and therapies.

  3. 7 Improvements in Clinical Supply Chain Management Your CFO Will Love 10/2/2023

    There is a great opportunity for clinical supply chain practitioners to learn from their commercial peers. By adapting and adopting the right commercial best practices, clinical supply chains become more effective, cost-efficient, and agile in delivering the right treatments to the right patients.

  4. Manufacturing Of Viral Vectors For Gene Therapy

    Viral vectors are essential for delivering corrected genetic information to faulty genes within affected cells and are at the heart of the gene therapy process.

  5. Biology Meets Computer Science For Next-Gen Biologics Drug Discovery 11/15/2022

    We have entered a new age in biologics development, which is undergoing a technological revolution with an increasing focus on software-dependent and data-driven results. Integrating the biological and the computational creates a need for specialists working together in parallel.

  6. Targeted Protein Degradation: Challenges And Opportunities 8/1/2022

    Degradation is a significantly different modality from small molecule inhibition, as PROTACs have a catalytic mode of action, event-driven pharmacology, and can target undruggable proteins with shallow pockets.

  7. Batch Records Review vs. MES Software 4/27/2023

    Learn how more life sciences companies are implementing manufacturing execution systems (MES) to improve quality at every step and get products to patients faster.

  8. A Proven AAV Platform To Drive Down Program Costs And Maximize Speed

    To ensure that your adeno-associated virus (AAV) therapy reaches patients as soon as possible, begin your relationship with an experienced AAV manufacturer early in the development journey.

  9. Seven Softgel Myths: Are You Missing Your Softgel Opportunity?

    Softgels are a popular dose format among consumers, thanks to their high swallowability and quick onset of action, yet pharmaceutical developers may not even consider them. Why the disconnect?

  10. De-Risking Cell Therapy Development: 4 Keys To A Streamlined IND Path 10/23/2024

    The first in a two-part series focuses on the initial stages of product development — specifically, how to move from candidate selection to a Phase 1 IND application.